The growth of Viagra and its effect on the pharmaceutical landscape presents a complex question for investors. While the first sales figures were remarkable, the patent has ended, leading to a deluge of generic alternatives that are reducing profit. Moreover, the sector is facing issues related to aging trends and shifting healthcare guidelines, ma